LITTLE KNOWN FACTS ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS.

In Phase A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to recognize Protected dosing regimen. Supplemental members is going to be enrolled in the discovered monotherapy dosign routine. In Phase B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, participants